Trial Profile
An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2019
Price :
$35
*
At a glance
- Drugs BAY 1238097 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 31 Jan 2019 Results published in the European Journal of Cancer
- 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 10 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.